Optimising the use of tazarotene in clinical practice: Consensus statement from the European Advisory Panel for tazarotene (Zorac(TM))

Dermatology

Volumn 199, Issue 1, 1999, Pages 40-46

  Gollnick, H P M ^a   Finzi, A F ^f   Marks, R ^b   Barker, J N W N ^c   Jansen, C ^f   Revuz, J ^d   Saurat, J H ^e  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d HENRI MONDOR HOSPITAL   (France)

^e Hôpital Cantonal   (Switzerland)

^f Otto von Guericke Universität Klin fur Dermatol und Venerologie ^*

Author keywords

Corticosteroid; Phototherapy; Psoriasis; Retinoid; Tazarotene

Indexed keywords

CORTICOSTEROID; RETINOID; TAZAROTENE;

BODY SURFACE; DRUG EFFICACY; DRUG USE; FACE; HUMAN; LIMB; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; REVIEW; SCALP; SKINFOLD; THICKNESS; TOPICAL DRUG ADMINISTRATION; TRUNK; ULTRAVIOLET B RADIATION;

EID: 0032811176     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018176     Document Type: Review

References (14)

1. Gollnick HPM: Oral retinoids - Efficacy and toxicity in psoriasis. Br J Dermatol 1996;135: 6-17.
2. Fisher GJ, Talwar HS, Xiao JH, Datta SC, Reddy AP, Gaub MP, Rochette-Egly C, Chambon P, Voorhees JJ: Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem 1994;269:20629-20635.
3. Chandraratna RAS : Tazarotene - First of a new generation of receptor-selective retinoids. Br J Dermatol 1996;135:18-25.
4. Matsumoto RM, Sun H, Tang-Lui D: Species correlation of AGN 190168 disposition in mouse, hamster, rat, rabbit, monkey and man. Pharm Res 1992;9(suppl):274.
5. Nagpal S, Athanikar J, Chandraratna RAS. Separation of transactivation and API antagonism functions of retinoic acid receptor α. J Biol Chem 1995;270:923-927.
6. Halkier-Sorenson L, Laurberg G, Andresen J: Bone changes in children on long-term treatment with etretinate. J Am Acad Dermatol 1987;16:999-1006.
7. Geiger JM, Baudin M, Saurat JH: Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994;189:109-116.
8. Marks R: Clinical safety of tazarotene in the treatment of plaque psoriasis. J Am Acad Dermatol 1997;37:S25-S32.
9. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, Jorizzo JL, Shmunes E, Tschen EH, Lew-Kaya DA, Lue JC, Sefton J, Gibson JR, Chandraratna RAS: Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92.
10. Krueger GG, Drake LA, Elias PM, Lowe NJ, Guzzo C, Weinstein GD, Lew-Kaya DA, Lue JC, Sefton J, Chandraratna RAS: The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998;134:57-60.
11. Lebwohl M, Ast E, Gallen JP, Cullen SI, Hong SR, Kulp-Shorten CL, Lowe NJ, Phillips TJ, Rosen T, WoIf DI, Quell JM, Sefton J, Lue JC, Gibson JR, Chandraratna RAS: Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38:705-711.
12. Lebwohl BG, Breneman DL, Goffe SB, Grossman JR, Ling MR, Milbauer J, Pincus SH, Swinyer LJ, Weinstein GD, Lew-Kaya DA, Lue JC, Gibson JR, Sefton J: Tazarotene 0.1 % gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 39:590-596.
13. Koo JY: Tazarotene in combination with phototherapy. J Am Acad Dermatol 1998;39:S144-148.
14. Gollnick H, Menter A: Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999;140(suppl 54):18-23.